Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6aAjqyO
via IFTTT